Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma

Summary

This phase II trial investigates the effect of olaparib in treating patients with castration resistant prostate adenocarcinoma. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start

2022-11-09

Primary completion

2023-10-15

Completion

2023-10-15

Outcome

Outcome not reported

Stopped (Business): “Withdrawal of funding”

Drugs

Indications